# TRPA1 exacerbates selective retinal ganglion cell vulnerability under acute ocular hypertension

**Authors:** Wenhan Lu, Yu Wang, Wei Hu, Xinyi Lin, Xiaoyu Tong, Yi Tian, Yuning Chen, Yicong Wang, Yan Xiao, Hongfang Yang, Yi Feng, Xinghuai Sun

PMC · DOI: 10.1186/s40478-025-01974-5 · Acta Neuropathologica Communications · 2025-04-05

## TL;DR

This study shows that TRPA1 worsens retinal ganglion cell damage in acute ocular hypertension, offering a new therapeutic target.

## Contribution

The study identifies TRPA1 as a key factor in selective retinal ganglion cell vulnerability under acute ocular hypertension.

## Key findings

- TRPA1 activation is observed in retinal ganglion cells during acute ocular hypertension.
- TRPA1 exacerbates retinal ganglion cell degeneration and selective injury under acute ocular hypertension.
- A modified whole-brain clearing method reveals region-specific axonal damage in lateral geniculate nuclei subregions.

## Abstract

Acute ocular hypertension (AOH), a major cause of progressive irreversible vision loss, showed significant retinal ganglion cell (RGC) degeneration as well as selective RGC vulnerability upon functional tests, yet the underlyding mechanisms remain incompletely understood. Here, we report the activation of transient receptor potential ankyrin 1 (TRPA1), a mechanosensitive ion channel on RGCs under AOH by RT-qPCR, Western blot, immunofluorescent, flow cytometry and calcium imaging tests. Downstream CaMKII/CREB pathways were evaluated, showing significantly elevated phospho-CaMKII and down-regulated phospho-CREB1 under AOH. Further, by applying a modified whole-brain clearing method, the region-specific RGC axonal damage among lateral geniculate nuclei (LGN) subregions were adopted to detect the involvement of TRPA1 on selective RGC vulnerability. Together with tissue-specific knock-out or channel inhibition test, the exacerbation of TRPA1 on RGC degeneration as well as selective injury tendency under AOH was confirmed. In virtue of our modified whole-brain clearing method, our data confirmed the innovational method to study the mechanisms behind selective vulnerability of neuronal cells, and in the meantime revealed the potential therapeutic opportunity of targeting TRPA1 for patients suffering from AOH attack.

The online version contains supplementary material available at 10.1186/s40478-025-01974-5.

## Linked entities

- **Genes:** TRPA1 (transient receptor potential cation channel subfamily A member 1) [NCBI Gene 8989], CAMK2G (calcium/calmodulin dependent protein kinase II gamma) [NCBI Gene 818], CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385]

## Full-text entities

- **Genes:** CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385] {aka CREB, CREB-1}, TRPA1 (transient receptor potential cation channel subfamily A member 1) [NCBI Gene 8989] {aka ANKTM1, FEPS, FEPS1, p120}, CAMK2G (calcium/calmodulin dependent protein kinase II gamma) [NCBI Gene 818] {aka CAMK, CAMK-II, CAMKG, MRD59}
- **Diseases:** AOH (MESH:D009798), vision loss (MESH:D014786), axonal damage (MESH:D001480), RGC degeneration (MESH:D012162)
- **Chemicals:** calcium (MESH:D002118)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11971892/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11971892/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC11971892/full.md

---
Source: https://tomesphere.com/paper/PMC11971892